Technology | Stent Grafts | January 31, 2017

FDA Approves First Balloon Expandable Stent Graft for Use in the Iliac Artery

Gore Viabahn VBX Balloon Expandable Endoprosthesis provides improved outcomes in real-world peripheral arterial disease cases

Gore, Viabahn VBX Balloon Expandable Endoprosthesis, stent graft, iliac artery, FDA approval

January 31, 2017 — W. L. Gore & Associates (Gore) announced that the Gore Viabahn VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) has received U.S. Food & Drug Administration (FDA) approval for treatment of de novo or restenotic lesions found in iliac arteries. The approval includes lesions at the aortic bifurcation. This marks the availability of the only balloon expandable stent graft with an indication for the iliac artery.

“The VBX Stent Graft demonstrated notable immediate and nine-month safety and efficacy in treating patients with iliac occlusive disease which can be attributed to the exceptional device design,” said Jean Bismuth, M.D.

Bismuth continued, “Overall, there were multiple clinical benefits observed, including no median change in the device length upon deployment, and a 100 percent technical success rate with no occurrences of stent dislodgement or significant residual stenosis. The study device performed well in disadvantaged lesions, including occlusions, which speaks to its trackability, radial strength, conformability, and stent retention.”

Of the patients in the Gore VBX FLEX IDE clinical study (n=134), 32 percent presented with TASC II type C or D lesions, 18 percent required contralateral access to the lesion, and 42 percent involved kissing stents at the aortic bifurcation. Clinical data from the study conducted for FDA approval reflected that the design components of the VBX Stent Graft were resilient both during stenting procedures and over time:

  • 100 percent success rate in device delivery and coverage of target lesions in all study subjects;
  • 100 percent success rate in reducing the target lesion to less than or equal to 30 percent of the original stenosis;
  • Zero change in median length of the device upon deployment; and
  • 96.9 percent primary patency at nine-months, including a 95.3 percent primary patency rate in those patients with TASC II C or D type lesions.

Further, there were no reported incidences of device dislodgement, failures in stent integrity or device-related serious adverse events through the primary endpoint follow-up, meaning no additional costs incurred for either endovascular or surgical stent removal. The VBX Stent Graft does not require pre-dilation, which reduces the number of balloons required, and the longer lengths available reduce the need to use multiple stents for extensive lesions, both of which also contribute to procedural cost savings.

The VBX Stent Graft was developed utilizing the small diameter, ePTFE stent graft technology from the Gore Viabahn Endoprosthesis. The VBX Stent Graft is available in a range of diameters from 5 to 11 millimeters and lengths of 15, 19, 29, 39, 59 and 79 millimeters to cover a wide variety of treatment needs.

For more information: www.goremedical.com

Related Content

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Overlay Init